Sale of Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma supports AstraZeneca’s strategy of focusing on pipeline of new medicines
AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs).
The agreement excludes the rights in the US and India, which were previously divested, and in Japan, which will be retained by AstraZeneca. The medicines, used primarily to treat hypertension, have lost their patent protection globally.
Ruud Dobber, Executive Vice President, BioPharmaceuticals, said: “These are important established medicines, and the divestment to Atnahs ensures they will continue to be available to patients. This transaction supports our strategy to realise value from our portfolio of non-core mature brands, enabling further investment in new medicines.”
AstraZeneca will continue to manufacture and supply Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs during a transition period.
Market Insights Reports has published a recent study which takes into account these and many other key market developments which have a significant impact on the segment. As per the study
The asthma and COPD drugs market is expected to witness a CAGR of 4.2% during the forecast period.
Asthma is Expected to Hold the Largest Market Share in the Indication Type
According to the American Academy of Allergy Asthma and Immunology (AAAI), in 2016, approximately 8.3% of children in the United States were found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively. Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010, and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among the sub-demographic groups, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016.
North America Dominates the Market and Expected to do Same in the Forecast Period
According to the AAAI, in 2012, the median annual medical cost of asthma was USD 983 in the United States. This ranged from an average low of USD 833 in Arizona to an average high of USD 1,121 in Michigan. In addition, there were 3,615 asthma-related deaths in 2015. Children under 18 years old made up 219 of those deaths. Asthma prevalence was the highest among workers in the healthcare and social assistance industry, with 8.8% of workers stating that they had asthma at the time of the survey. Workers in the educational services industry reported the second-highest rate (8.2%) of asthma prevalence. Hence, the growing prevalence of asthma is expected to contribute to the significant market share of the North American market over the forecast period.
The asthma and COPD drugs market is highly competitive and consists of few major players. Companies, like GlaxoSmithKline, Novartis, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer, among others, hold the substantial market share in the asthma and COPD drugs market.
Buy Now This Report:
MarketInsightsReports (An Ameliorate Solutions Group Company) provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234